Login / Signup

Positive clinical outcome using a modified dosing regimen of benznidazole in dogs at high risk for infection or acutely infected with Trypanosoma cruzi.

Sukjung LimStephanie CollinsSarah A HamerRick L TarletonAshley B Saunders
Published in: Journal of veterinary internal medicine (2024)
Trypanosoma cruzi infection in dogs can cause heart failure and sudden death with few treatment options available. A litter of 4 dogs living in a T cruzi endemic area were randomized to prophylaxis and nonprophylaxis groups as part of a study evaluating a modified benznidazole dosing regimen administered twice weekly to prevent T cruzi infection during a vector transmission season. The 2 dogs that received prophylaxis remained healthy without T cruzi infection or cardiac disease for >2 years. One dog that did not receive prophylaxis died unexpectedly with acute T cruzi-induced pancarditis, and the second dog tested positive for T cruzi and developed complex arrhythmias with markedly increased cardiac troponin I and improved with a higher benznidazole treatment dose. Although the small sample size precludes definitive conclusions, we describe the potential clinical benefit of prophylactic and early treatment with modified benznidazole dosing regimens for dogs with T cruzi infection.
Keyphrases
  • trypanosoma cruzi
  • heart failure
  • liver failure
  • squamous cell carcinoma
  • open label
  • risk assessment
  • hepatitis b virus
  • intensive care unit
  • respiratory failure
  • human health
  • phase ii
  • cardiac resynchronization therapy